Q1 IR Roundtable Event: How ESG Drives Trust Among Investors and Patients Alike

Published 13 days ago • 1 min read

HI!

Regardless of whether IR is formally in your remit, ESG conversations are showing up everywhere right now... in earnings prep, in board discussions, in analyst questions, and increasingly in conversations about patient trust.

Investors are evaluating governance, capital discipline, and long-term risk. But in our industry, ESG carries a different weight because patients and advocacy communities are watching how companies show up on access, equity, and corporate responsibility.

That’s what T2B's Q1 IR Roundtable event will explore:

Beyond the Checkbox: How ESG Drives Trust Among Investors and Patients Alike

🗓️ Friday, March 13th | 12-12:45 p.m. ET
Sign up here
Exclusive to T2B Pro and Student members

We’ll explore:

How different types of investors are actually interpreting and applying ESG information
The role of ratings agencies and external benchmarks
Where ESG intersects with governance, DEI, access, and patient centricity
How IR and corporate affairs leaders are structuring the narrative so it holds up with analysts, boards, and employees alike

Our speakers bring perspective from biotech, large pharma, and strategic advisory roles:

Elizabeth Higgins, Former Head of Corporate Communications and Investor Relations, Astria Therapeutics, and T2B IR Roundtable Member
Sri Ramaswami, Founder and Principal, Sri Spoke Communications LLC
Moderated by David Connolly, Head of Investor Relations and Corporate Communications, Rhythm Pharmaceuticals, and T2B IR Roundtable Member

Looking forward to this one!

Lynnea

PS - I hope our friends on the East Coast are staying safe and warm amid the blizzard! We'll be rescheduling this week's meetups in Boston and Princeton soon.

Recap: Fighting Misinformation Without Amplifying It

Hi! At our February Comm Convo, Fighting Misinformation Without Amplifying It, we examined the practical reality biopharma communicators navigate every day: A fast-moving information environment where incomplete, misleading, or distorted claims can gain traction quickly. There is rarely a clean or standard how-to for responding when misinformation spreads. Instead, effective responses depend on preparation, cross-functional alignment, and disciplined judgment about when engagement adds...

4 days ago • 2 min read

Tomorrow's Panel ➡️ Patient Stories Without a Fixed Address

Hi! A quick reminder that tomorrow is our inaugural PA&E Roundtable event. Wherever the patient advocacy function formally sits in an organization research, communicators are often the ones helping translate those patient insights into stories that resonate internally and externally. Tomorrow’s conversation will explore how teams gather those insights, how communicators partner across functions, and what it takes to represent patient experiences thoughtfully and responsibly in our work. The...

5 days ago • 1 min read

The Outsider Advantage: Cross-Industry Comms Insights

Hi! As we know all too well, life sciences comms comes with a unique set of complexities, from regulatory constraints, to deep investor scrutiny, to audiences with technical expectations. But many of the challenges we face aren’t truly one-of-a-kind to our sector. Across industries, communicators wrestle with trust, ambiguity, executive counsel under pressure, and shifting stakeholder dynamics. Our March Comm Convo brings together communicators who have worked in and out of life sciences to...